Pancreatic Cancer Research

ResearcherZhejiang Chinese Medical UniversityActive in the last 2 years

Jian Xu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-8132-8988; OpenAlex author ID A5100760825. Sources: OpenAlex.

Their work

Papers
8 (first author 1, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
20
Papers, trials and grants by year

2021: 2 papers · 2022: none · 2023: 3 papers · 2024: 1 paper · 2025: none · 2026: 2 papers

Papers 8

  1. LRP1 regulates GDNF secretion and perineural invasion in pancreatic cancer via PI3K/AKT signaling. Last author DOI 10.1016/j.cellsig.2025.112225↗
  2. Single-cell RNA sequencing uncovers an immunosuppressive program in PDAC mast cells: tumour-driven activation, proliferation, and association with Treg recruit… Last author DOI 10.1080/07853890.2026.2724762↗
  3. Targeting cancer-associated fibroblast autophagy renders pancreatic cancer eradicable with immunochemotherapy by inhibiting adaptive immune resistance. Co-author DOI 10.1080/15548627.2023.2300913↗
  4. Targeting MFAP5 in cancer-associated fibroblasts sensitizes pancreatic cancer to PD-L1-based immunochemotherapy via remodeling the matrix. Co-author DOI 10.1038/s41388-023-02711-9↗
  5. Targeting ubiquitin-specific protease 8 sensitizes anti-programmed death-ligand 1 immunotherapy of pancreatic cancer. Co-author DOI 10.1038/s41418-022-01102-z↗
  6. Galectin-9 and PD-L1 antibody blockade combination therapy inhibits tumour progression in pancreatic cancer. First author DOI 10.2217/imt-2021-0075↗
  7. Regulator of calcineurin 1 gene isoform 4 in pancreatic ductal adenocarcinoma regulates the progression of tumor cells. Co-author DOI 10.1038/s41388-021-01763-z↗
  8. NEK2 inhibition triggers anti-pancreatic cancer immunity by targeting PD-L1. Co-author DOI 10.1038/s41467-021-24769-3↗

Closest collaborators

The 20 strongest of 20 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Xiaozhen Zhang · 6 shared papers, 2021–2024 · strength 0.94
  2. Tingbo Liang · 6 shared papers, 2021–2024 · strength 0.94
  3. Xueli Bai · 5 shared papers, 2021–2024 · strength 0.73
  4. Songmei Lou · 2 shared papers, 2026 · strength 0.62
  5. Hanshen Yang · 4 shared papers, 2021–2024 · strength 0.61
  6. Mengyi Lao · 4 shared papers, 2021–2024 · strength 0.55
  7. Lihong He · 3 shared papers, 2023–2024 · strength 0.49
  8. Kang Sun · 3 shared papers, 2023–2024 · strength 0.49
  9. Yi Duan · 3 shared papers, 2021–2023 · strength 0.44
  10. Enliang Li · 2 shared papers, 2021–2023 · strength 0.34
  11. Mengli Wu · 1 shared paper, 2026 · strength 0.32
  12. Mengying Zhu · 1 shared paper, 2026 · strength 0.30
  13. Shenhao Liu · 1 shared paper, 2026 · strength 0.30
  14. Qi Chen · 1 shared paper, 2023 · strength 0.22
  15. Yan Chen · 1 shared paper, 2023 · strength 0.15
  16. Tao Ma · 1 shared paper, 2021 · strength 0.12
  17. Gang Zhang · 1 shared paper, 2021 · strength 0.12
  18. Dipesh Kumar Yadav · 1 shared paper, 2021 · strength 0.12
  19. Xing Huang · 1 shared paper, 2021 · strength 0.12
  20. Tianyu Tang · 1 shared paper, 2021 · strength 0.12

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.